23 June 2020 : Laboratory Research
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
Xiaoqiu Wu123BEF, Fangfei Li123AG, Yongshu Li1BF, Yuanyuan Yu13DF, Chao Liang13C, Baoting Zhang4DE, Chuanzong Zhao56B, Aiping Lu12378AG, Ge Zhang123AG*DOI: 10.12659/MSM.925583
Med Sci Monit 2020; 26:e925583
Figure 6 The effect of XQ-P3 on the PD-1/PD-L1 interaction. (A) XQ-P3 gradually lost its binding to MDA-MB-231 PD-L1 OE cells when more PD-1 protein existed. MDA-MB-231 PD-L1 OE cells were preincubated with the indicated concentration of PD-1 protein before being incubated with Cy5-labeled XQ-P3 (250 nM). Competition binding was analyzed by flow cytometry. (B) T cells secreted elevated IL-2 after XQ-P3 treatment (n=3). RS, a random sequence served as a negative control of XQ-P3 aptamer.